tbuckley/cabot-search huggingface dataset:
Abstract 226: δ-opioid Receptor Activation Protects the Brain From Hypoxic-ischemic Injury by Downregulating Inflammatory Cytokines and Upregulating Nrf-2
Authors: Jie Qiu, Dongman Chao, Guanghong Ding, Ying Xia
Journal: Circulation Research (2016)

Hypoxia-ischemia (HI) insult induces inflammatory/oxidative injury and causes neurological disability and mortality. However, there are limited therapeutic options at present. Our recent studies have shown that the δ-opioid receptor (DOR) is neuroprotective against hypoxic-ischemic stress. In this work, we asked if DOR activation protects the brain against hypoxic-ischemic encephalopathy (HIE) by regulating inflammatory cytokines and Nrf-2, a basic leucine zipper protein that regulates the expression of antioxidant proteins. Our results showed that DOR activation with UFP-512 treatment significantly decreased TNF-α, IL-6, and ICAM-1 expression (P&lt;0.05) in the left cortex of the rat with HI injury, while DOR inhibition with naltrindole significantly increased their expression (P&lt;0.05). In contrast, DOR activation induced an opposite effect on IL-10 expression (P&lt;0.05) and had no appreciable effect on IL-18 (P&gt;0.05). In the control group, no significant difference was detected after the vehicle treatment. Furthermore, we investigated the role of Nrf-2 in the DOR neuroprotection since our recent data suggest that DOR signaling promotes the expression and relocation of Nrf2 and thus induces cytoprotection. HI significantly increased nuclear Nrf-2 protein, while DOR activation by pretreatment with UFP-512 before HI further elevated the level of nuclear Nrf-2 protein by 70% (P&lt;0.05) in the cortex. On the other side, DOR inhibition by the pretreatment with naltrindole completely abolished the HI- and DOR-induced increase in nuclear Nrf-2 protein. In the control, the vehicle treatment did not have any significant effect on nuclear Nrf-2 protein. These first data suggest that DOR activation protects the brain from HIE by downregulating the expression of inflammatory cytokines and upregulating Nrf-2 activity. This work was supported by NIH (AT-004422), Memorial Hermann’s Foundation and Vivian L Smith Neurologic Foundation. GD was supported by 973 Program (2012CB518502) and NSFC (81574053 &amp; 81590953) of China.
Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study
Authors: Ali T. Taher, Zeynep Karakas, Elena Cassinerio, Noppadol Siritanaratkul, Antonis Kattamis, Aurelio Maggio, Stefano Rivella, Norbert Hollaender, Bruyère Mahuzier, Brian Gadbaw, Yesim Aydinok
Journal: Blood (2017)
A situação da tuberculose em Portugal: uma perspectiva histórica até 1994
Authors: M L Antunes, A Fonseca-Antunes
Journal: Eurosurveillance (1996)

Em Portugal construiu-se o primeiro Sanatorio para tratamento da tuberculose (TB) em 1862 no Funchal. Em 1899, a Rainha D. Amelia patrocinou uma fundacao com uma rede de dispensarios, hospitais, sanatorios e preventorios onde doentes e familiares e outros conviventes de tuberculose eram acolhidos para vigilância e tratamento. Esta fundacao tornou-se um instituto publico em 1946. A Luta Contra a Tuberculose beneficiou sempre de grande apoio politico, social e publico e de generosos financiamentos para toda a assistencia gratuita, incluindo o fornecimento dos antibacilares mais recentes: Estreptomicina que foi introduzida em 1949, Rifampicina em 1966, e esquemas de tratamento curto em 1979.
Enfermedad de Creutzfeldt-Jakob: resultados de una encuesta llevada a cabo en los quince Estados Miembros de la Unión Europea
Authors: B. C. Merkel, P. W.J Peters, L Chambaud
Journal: Eurosurveillance (1996)

La enfermedad de Creutzfeldt-Jakob (ECJ) fue descrita por primera vez en 1920-1921. ECJ es una enfermedad poco habitual cuya incidencia notificada es de 0,5 a 1 caso por millon de personas en Europa (1). Esta demencia fatal pertenece a la categoria de Encefalopatias Espongiformes Transmisibles (EET) cuyas formas humanas incluyen el sindrome de Gerstmann-Straussler-Scheinker, el kuru y el insomnio familiar fatal, siendo todas ellas muy poco frecuentes. Las EET constituyen “un grupo de enfermedades degenerativas subagudas del cerebro, causadas por agentes filtrables ‘no convencionales’, con periodos de incubacion muy prolongados y sin respuesta inflamatoria ni inmune demostrable” (2). La ECJ se presenta con mayor frecuencia en su forma esporadica, si bien en aproximadamente el 10% de los casos puede encontrarse un origen genetico. La ECJ tambien se ha desarrollado despues de transplantes de organos o tratamientos con hormonas del crecimiento humano obtenidas de cadaveres infectados con el agente.
Double Kissing Crush Versus Provisional Stenting for Left Main Distal Bifurcation Lesions
Authors: Shao-Liang Chen, Jue-Jie Zhang, Yaling Han, Jing Kan, Lianglong Chen, Chunguang Qiu, Tiemin Jiang, Ling Tao, Hesong Zeng, Li Li, Yong Xia, Chuanyu Gao, Teguh Santoso, Chootopol Paiboon, Yan Wang, Tak W. Kwan, Fei Ye, Nailiang Tian, Zhizhong Liu, Song Lin, Chengzhi Lu, Shangyu Wen, Lang Hong, Qi Zhang, Imad Sheiban, Yawei Xu, Lefeng Wang, Tanveer S. Rab, Zhanquan Li, Guanchang Cheng, Lianqun Cui, Martin B. Leon, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2017)
TCT-545 Individualizing DAPT Duration after Coronary Stenting for Patients at High Bleeding Risk – The LEADERS FREE trade-off score
Authors: Philip Urban, John Gregson, Philipp Lurz, Bernard Chevalier, Marie-Claude Morice, Janusz Lipiecki, Franz-Josef Neumann, Stephen Lee, Andrejs Erglis, Samantha Greene, Stuart Pocock
Journal: Journal of the American College of Cardiology (2017)
Reply to I.J. Cohen
Authors: Kristina K. Hardy, Leanne M. Embry, John A. Kairalla, Shanjun Helian, Meenakshi Devidas, F. Daniel Armstrong, Stephen Hunger, William L. Carroll, Eric Larsen, Elizabeth A. Raetz, Mignon L. Loh, Wenjian Yang, Mary V. Relling, Robert B. Noll, Naomi Winick
Journal: Journal of Clinical Oncology (2017)
Predictors of Posthospital Transitions of Care in Patients With Advanced Cancer
Authors: Daniel E. Lage, Ryan D. Nipp, Sara M. D'Arpino, Samantha M. Moran, P. Connor Johnson, Risa L. Wong, William F. Pirl, Ephraim P. Hochberg, Lara N. Traeger, Vicki A. Jackson, Barbara J. Cashavelly, Holly S. Martinson, Joseph A. Greer, David P. Ryan, Jennifer S. Temel, Areej El-Jawahri
Journal: Journal of Clinical Oncology (2017)

Purpose Patients with advanced cancer experience potentially burdensome transitions of care after hospitalizations. We examined predictors of discharge location and assessed the relationship between discharge location and survival in this population. Methods We conducted a prospective study of 932 patients with advanced cancer who experienced an unplanned hospitalization between September 2014 and March 2016. Upon admission, we assessed patients’ physical symptoms (Edmonton Symptom Assessment System) and psychological distress (Patient Health Questionnaire-4). The primary outcome was discharge location (home without hospice, postacute care [PAC], or hospice [any setting]). The secondary outcome was survival. Results Of 932 patients, 726 (77.9%) were discharged home without hospice, 118 (12.7%) were discharged to PAC, and 88 (9.4%) to hospice. Those discharged to PAC and hospice reported high rates of severe symptoms, including dyspnea, constipation, low appetite, fatigue, depression, and anxiety. Using logistic regression, patients discharged to PAC or hospice versus home without hospice were more likely to be older (odds ratio [OR], 1.03; 95% CI, 1.02 to 1.05; P &lt; .001), live alone (OR, 1.95; 95% CI, 1.25 to 3.02; P &lt; .003), have impaired mobility (OR, 5.08; 95% CI, 3.46 to 7.45; P &lt; .001), longer hospital stays (OR, 1.15; 95% CI, 1.11 to 1.20; P &lt; .001), higher Edmonton Symptom Assessment System physical symptoms (OR, 1.02; 95% CI, 1.003 to 1.032; P &lt; .017), and higher Patient Health Questionnaire-4 depression symptoms (OR, 1.13; 95% CI, 1.01 to 1.25; P &lt; .027). Patients discharged to hospice rather than PAC were more likely to receive palliative care consultation (OR, 4.44; 95% CI, 2.12 to 9.29; P &lt; .001) and have shorter hospital stays (OR, 0.84; 95% CI, 0.77 to 0.91; P &lt; .001). Patients discharged to PAC versus home had lower survival (hazard ratio, 1.53; 95% CI, 1.22 to 1.93; P &lt; .001). Conclusion Patients with advanced cancer who were discharged to PAC facilities and hospice had substantial physical and psychological symptom burden, impaired physical function, and inferior survival compared with those discharged to home. These patients may benefit from interventions to enhance their quality of life and care.
Abstract 201: A Novel Contrast Agent - Magnetic Iodixanol
Authors: Mark C Arokiaraj
Journal: Circulation Research (2016)

Aims: The study was performed in search of a novel contrast agent, which has non-renal excretion. Contrast induced nephropathy and cardiogenic shock resulting in renal failure are common problems. A novel contrast with non-renal excretion is very useful. Materials and Methods: Magnetic nanoparticles were synthesized and it was conjugated with commercially available Iodixanol. The particle size measurement showed size of about 220nm. The conjugation was performed to result in covalent bonding. Final concentration of nanoparticles was 1mg in 1 ml. Thereafter the contrast was tested for radio-opacity. Magnetic properties of the contrast were tested with magnets. A drop of contrast was tested over magnets and over a glass slide. The droplet on the magnet fixes and retains the shape and the bubble structure in various positions of the magnet manipulation. Over a glass slide it showed free movement and loses the bubble structure. Figure shows bubble evaluation and cine-fluoroscopy. Conclusion: Magnetic nanoparticle conjugated Iodixanol shows potentials as a novel contrast agent for use in the future.
The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma
Authors: F. Bertucci, A. De Nonneville, P. Finetti, D. Perrot, M. Nilbert, A. Italiano, A. Le Cesne, K.M. Skubitz, J.Y. Blay, D. Birnbaum
Journal: Annals of Oncology (2017)
Location of Mutation in <i>BRCA2</i> Gene and Survival in Patients with Ovarian Cancer
Authors: S. Intidhar Labidi-Galy, Timothée Olivier, Manuel Rodrigues, Domenico Ferraioli, Olfa Derbel, Alexandre Bodmer, Patrick Petignat, Beata Rak, Nicolas Chopin, Olivier Tredan, Pierre-Etienne Heudel, Sarah Stuckelberger, Pierre Meeus, Patrick Meraldi, Valeria Viassolo, Aurélie Ayme, Pierre O. Chappuis, Marc-Henri Stern, Claude Houdayer, Dominique Stoppa-Lyonnet, Adrien Buisson, Lisa Golmard, Valérie Bonadona, Isabelle Ray-Coquard
Journal: Clinical Cancer Research (2017)

Purpose: BRCA2 plays a central role in homologous recombination by loading RAD51 on DNA breaks. The objective of this study is to determine whether the location of mutations in the RAD51-binding domain (RAD51-BD; exon 11) of BRCA2 gene affects the clinical outcome of ovarian cancer patients.Experimental Design: A study cohort of 353 women with ovarian cancer who underwent genetic germline testing for BRCA1 and BRCA2 genes was identified. Progression-free survival (PFS), platinum-free interval (PFI), and overall survival (OS) were analyzed. The Cancer Genome Atlas (TCGA) cohort of ovarian cancer (n = 316) was used as a validation cohort.Results: In the study cohort, 78 patients were carriers of germline mutations of BRCA2 After adjustment for FIGO stage and macroscopic residual disease, BRCA2 carriers with truncating mutations in the RAD51-BD have significantly prolonged 5-year PFS [58%; adjusted HR, 0.36; 95% confidence interval (CI), 0.20-0.64; P = 0.001] and prolonged PFI (29.7 vs. 15.5 months, P = 0.011), compared with noncarriers. BRCA2 carriers with mutations located in other domains of the gene do not have prolonged 5-year PFS (28%, adjusted HR, 0.67; 95% CI, 0.42-1.07; P = 0.094) or PFI (19 vs. 15.5 months, P = 0.146). In the TCGA cohort, only BRCA2 carriers harboring germline or somatic mutations in the RAD51-BD have prolonged 5-year PFS (46%; adjusted HR, 0.30; 95% CI, 0.13-0.68; P = 0.004) and 5-year OS (78%; adjusted HR, 0.09; 95% CI, 0.02-0.38; P = 0.001).Conclusions: Among ovarian cancer patients, BRCA2 carriers with mutations located in the RAD51-BD (exon 11) have prolonged PFS, PFI, and OS. Clin Cancer Res; 24(2); 326-33. ©2017 AACR.
Direction of leukocyte polarization and migration by the phosphoinositide-transfer protein TIPE2
Authors: Svetlana A Fayngerts, Zhaojun Wang, Ali Zamani, Honghong Sun, Amanda E Boggs, Thomas P Porturas, Weidong Xie, Mei Lin, Terry Cathopoulis, Jason R Goldsmith, Anastassios Vourekas, Youhai H Chen
Journal: Nature Immunology (2017)
P3.02b-064 Time to EGFR-TKI Treatment for Patients with Advanced NSCLC and EGFR Activating Mutation in a Tertiary Cancer Center
Authors: Jennifer Le Guévelou, Audrey Dugué, Nicolas Richard, Catherine Dubos, Pascal Dô, Serge Danhier, Delphine Lerouge, Jessica Bonneau, Cécile Blanc, Radj Gervais
Journal: Journal of Thoracic Oncology (2017)
TCT-791 Impact of Clinical Judgement on Risk Stratification of Patients at High Risk for TAVR: A BRAVO-3 Subgroup Analysis
Authors: Matias Yudi, Roxana Mehran, Thierry Lefevre, John Webb, Eric Van Belle, Annapoorna Kini, Samin Sharma, David Hildick-Smith, Rainer Hambrecht, Julian Widder, Sabato Sorrentino, Serdar Farhan, Samantha Sartori, Jaya Chandrasekhar, Prodromos Anthopoulos, Christian Hengstenberg, George Dangas
Journal: Journal of the American College of Cardiology (2017)
Deep remission induced by triplet therapy with afatinib, cetuximab and bevacizumab in lung cancer cells harboring T790M
Authors: Kenichirou Kudou, Kadoaki Ohashi, Eiki Ichihara, Takashi Ninomiya, Toshio Kubo, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura
Journal: Annals of Oncology (2017)
Interleukin-13- and Tansforming Growth Factor-β- Producing Mast Cells Are Associated with Fibrosis in Bone Marrow
Authors: Shoko Nakayama, Taiji Yokote, Nobuya Hiraoka, Toshikazu Akioka, Takuji Miyoshi, Kazuki Iwaki, Ayami Fumimoto, Uta Nishiwaki, Yuki Masuda, Jun Hatooka, Mayumi Fujimoto, Motomu Tsuji
Journal: Blood (2016)
Results from the European Prospective Investigation into Cancer and Nutrition Link Vitamin B6 Catabolism and Lung Cancer Risk
Authors: Hui Zuo, Per M. Ueland, Øivind Midttun, Stein E. Vollset, Grethe S. Tell, Despoina Theofylaktopoulou, Ruth C. Travis, Marie-Christine Boutron-Ruault, Agnès Fournier, Gianluca Severi, Marina Kvaskoff, Heiner Boeing, Manuela M. Bergmann, Renée T. Fortner, Rudolf Kaaks, Antonia Trichopoulou, Anastasia Kotanidou, Pagona Lagiou, Domenico Palli, Sabina Sieri, Salvatore Panico, H. Bas Bueno-de-Mesquita, Petra H. Peeters, Kjell Grankvist, Mikael Johansson, Antonio Agudo, Jose Ramon Quiros Garcia, Nerea Larranaga, Maria-Jose Sanchez, Maria Dolores Chirlaque, Eva Ardanaz, Shu-Chun Chuang, Valentina Gallo, Paul Brennan, Mattias Johansson, Arve Ulvik
Journal: Cancer Research (2017)

Circulating pyridoxal-5'-phosphate (PLP) has been linked to lung cancer risk. The PAr index, defined as the ratio 4-pyridoxic acid/(pyridoxal + PLP), reflects increased vitamin B6 catabolism during inflammation. PAr has been defined as a marker of lung cancer risk in a prospective cohort study, but analysis of a larger numbers of cases are needed to deepen the significance of this study. Here, we conducted a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC,
Una estrategia para mejorar y evaluar la cobertura vacunal en el norte de Portugal
Authors: G Gonçalves, M A Frutuoso, M C Ferreira, M G Freitas
Journal: Eurosurveillance (2005)

En el area sanitaria del norte de Portugal, se midio la cobertura vacunal a partir de registros individuales (previamente verificados) de vacunas de los centros de salud. Cada ano entre 2001 y 2004, fueron seleccionadas para la evaluacion cohortes por fecha de nacimiento (ninos de mas de 2, 6 o 14 anos). Los datos se recogian en enero del ano siguiente, y cada marzo se organizaban reuniones con los coordinadores de vacunacion por distrito. Las coberturas vacunales observadas en el norte de Portugal fueron optimas para todas las vacunas y cohortes de nacimiento consideradas. En este articulo se hacen comparaciones con los datos de la literatura internacional sobre la cobertura vacunal y se discute sobre la validez de los resultados. Creemos que los datos de cobertura vacunal que aqui se presentan no sufren de sesgos importantes, aunque las comparaciones con datos internacionales deben hacerse con precaucion. Los metodos que aqui se utilizan pueden contribuir a mejorar la cobertura vacunal.
Doações de sangue na Alemanha em 2000-2002 : o risco de transmissão viral e o impacto do teste de ácidos nucleicos (NAT)
Authors: Ruth Offergeld, D Faensen, S Ritter, O Hamouda
Journal: Eurosurveillance (2005)

Na Alemanha, as doacoes de sangue e de plasma sao recolhidas por varios organismos, que sao a Cruz Vermelha alema, os servicios de transfusao publicos e dos hospitais, os centros de transfusao privados, os estabelecimentos comerciais de doacoes de sangue e os servicios de transfusao do exercito. Cada trimestre, os centros de transfusao devem declarar ao Instituto Robert Koch os dados sobre os marcadores de infeccoes para serem disponiveis dados epidemiologicos detalhados e actualizados. A prevalencia e a incidencia de infeccoes virais importantes sao baixas na populacao de dadores de sangue na Alemanha, com uma tendencia decrescente desde 1997 para as infeccoes da hepatite C, tanto em dadores de repeticao como nos novos dadores. O implemento do NAT para o virus da hepatite C (VHC), obrigatorio desde 1999, melhorou consideravelmente a seguranca dos componentes do sangue. Para o VIH, o NAT e obrigatorio desde 2004, mas ja se usava de forma voluntaria na maioria dos servicios de transfusao de sangue. O proveito potencial do NAT em minipool nao e evidente para o virus da hepatite B (VHB), visto que os portadores cronicos com uma carga viral muito baixa podriam dar sangue sem serem identificados. O risco residual durante o periodo  de uma doacao fazendo parte de um lote de sangue, pode-se estimar com a formula matematica seguinte : taxa de incidencia multiplicada pelo numero de dias durante os quais a infeccao pode estar presente mas nao detectavel, ou seja a duracao do periodo janela serologica. 
Em 2001-2002, sem NAT, estimava-se o risco de uma infeccao nao detectada em 1 por 2.770.000 para o VIH, 1 por 670.000 para o VHC e 1 por 230.000 para o VHB. Com NAT em minipool, este risco representa 1 por 5.540.000 para o VIH, 1 por 4.400.000 para o VHC e 1 por 620.000 para o VHB. Estes resultados mostram que a utilizacao do NAT reduz ainda mais o risco de doacoes infecciosas, risco ja muito baixo.
Synopsis of the 2017 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: Management of Type 2 Diabetes Mellitus
Authors: Paul R. Conlin, Jeffrey Colburn, David Aron, Rose Mary Pries, Mark P. Tschanz, Leonard Pogach
Journal: Annals of Internal Medicine (2017)

In April 2017, the U.S. Department of Veterans Affairs (VA) and the U.S. Department of Defense (DoD) approved a joint clinical practice guideline for the management of type 2 diabetes mellitus.The VA/DoD Evidence-Based Practice Work Group convened a joint VA/DoD guideline development effort that included a multidisciplinary panel of practicing clinician stakeholders and conformed to the Institute of Medicine's tenets for trustworthy clinical practice guidelines. The guideline panel developed key questions in collaboration with the ECRI Institute, which systematically searched and evaluated the literature through June 2016, developed an algorithm, and rated recommendations by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.This synopsis summarizes key features of the guideline in 7 areas: patient-centered care and shared decision making, glycemic biomarkers, hemoglobin A1c target ranges, individualized treatment plans, outpatient pharmacologic treatment, glucose targets for critically ill patients, and treatment of hospitalized patients.
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Authors: Antonio Omuro, Gordana Vlahovic, Michael Lim, Solmaz Sahebjam, Joachim Baehring, Timothy Cloughesy, Alfredo Voloschin, Shakti H Ramkissoon, Keith L Ligon, Robert Latek, Ricardo Zwirtes, Lewis Strauss, Prashni Paliwal, Christopher T Harbison, David A Reardon, John H Sampson
Journal: Neuro-Oncology (2017)

Immunotherapies have demonstrated efficacy across a diverse set of tumors supporting further evaluation in glioblastoma. The objective of this study was to evaluate the safety/tolerability and describe immune-mediated effects of nivolumab ± ipilimumab in patients with recurrent glioblastoma. Exploratory efficacy outcomes are also reported.
A Common Toolbox to Understand, Monitor or Manage Rarity? A Response to Carmona et al.
Authors: Cyrille Violle, Wilfried Thuiller, Nicolas Mouquet, François Munoz, Nathan J.B. Kraft, Marc W. Cadotte, Stuart W. Livingstone, Matthias Grenie, David Mouillot
Journal: Trends in Ecology & Evolution (2017)
Abstract 14915: Paradoxical Effect of Genetic Deletion of Nox2 in Endothelial-specific Insulin Resistant Mice on Development of Atherosclerosis
Authors: Nadira Y Yuldasheva, Anna Skromna, Natalia Makava, Azhar Maqbool, Galina Nikanorova, Richard M Cubbon, Stephen B Wheatcroft, Mark T Kearney
Journal: Circulation (2016)

Global and endothelium-specific insulin resistance is associated with accelerated atherosclerosis and increased Nox2 NADPH oxidase derived superoxide. We therefore investigated the impact of geneti...
A NHO network surveillance for constructing the safe handling system of hazardous drugs in Japan (2nd report)
Authors: Kenjiro Aogi, Kenichi Watanabe, Takanori Watanabe, Tetsu Matsui, Yasuyuki Sato, Norikazu Masuda, Yoshinori Yamashita, Shinya Ohtsuka, Eriko Tokunaga, Setsuko Anami
Journal: Annals of Oncology (2017)
TCT-821 One-year clinical outcome of a newer generation DES in diabetes mellitus patients: insight from ongoing “en-ABL” e-registry
Authors: Luca Testa, Sameer Dani, Rashmit Pandya, Apurva Vasavada, Chirag Sheth, Rutvik Trivedi, Kushal Pujara
Journal: Journal of the American College of Cardiology (2017)
Acção Concertada Europeia sobre a Doença de Lyme (ACEUDL)
Authors: S O’Connell
Journal: Eurosurveillance (1996)

As incertezas que persistem sobre a doenca de Lyme, o risco de sequelas graves e o facto de as tecnicas laboratoriais serem insatisfatorias levaram a que investigadores de 12 paises da Uniao Europeia (UE), e de dois paises do ex-bloco leste europeu, unissem os seus esforcos num projecto de colaboracao. A Accao Concertada Europeia sobre a Doenca de Lyme (ACEUDL), financiada pela UE ao abrigo do programa BIOMED I, sob a orientacao do Dr. Jeromy Gray da Universidade de Dublin, coordena a investigacao sobre a ecologia, a biologia molecular, a taxonomia e a distribuicao geografica da Borrelia burgdorferi na Europa; os aspectos clinicos e epidemiologicos da borreliose de Lyme na Europa, os factores de risco da infeccao no homem; medidas de prevencao, incluindo programas de educacao orientados para areas endemicas.
TCT-447 Improved Outcomes in Patients with Bicuspid Aortic Valve Disease with Evolut R Self-Expanding Transcatheter Aortic Valve Replacement: A Report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy RegistryTM
Authors: Jeffrey J. Popma, Michael J. Reardon, Stanley Chetcuti, David H. Adams, Susheel Kodali, Paul Sorajja, James B. Hermiller, Wilson Y. Szeto
Journal: Journal of the American College of Cardiology (2017)